PDC and Parkinson disease: Among PHD inhibitors, compounds that do not bind iron show greater promise for the treatment of PD and others neurodegenerative disorders, since chronic administration of chelators can lead to restless legs syndrome (RLS) (Earley et al., 2014) or anemia (White et al., 2005).